Searched for
NOVO NORDISK BID
Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...- European shares rally as Middle East peace hopes drag oil prices lowerEuropean shares surged on Friday, driven by renewed hopes for a Middle East diplomatic breakthrough that lowered oil prices. The pan-Europe...
- Novo rebrands diabetes pill as Ozempic to tap blockbuster nameNovo Nordisk is relaunching a diabetes tablet as Ozempic in the United States. This move aims to boost sales by using the strong brand reco...
- US Stocks | Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats upKailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....
- Emcure cuts semaglutide injection price by average 47%The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pe...
- Glenmark set to join peers in 'Semaglutide' pushGlenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalate...
- Slimmer price tag helps Wegovy sales gain weightNovo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...
- Eli Lilly becomes first healthcare firm to hit $1 trillion market cap - here’s why LLY stock has jumped over 36% this yearEli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...
- Novo, Emcure to launch weight-loss drug under new brand in IndiaIn June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the compan...
- Novo Nordisk ties up with Emcure to expand reach of weight-loss drug semaglutide in IndiaNovo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand n...
- Pfizer to acquire obesity drug startup Metsera in $10 billion dealPfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...
- Metsera accepts Pfizer's $10 billion bid in ongoing M&A battleMetsera has accepted Pfizer's $10 billion acquisition offer. This ends a bidding war with rival Novo Nordisk. Pfizer will pay $86.25 per sh...
- Pfizer weighs sweeter offer for Metsera after Judge blocks bid to halt Novo Nordisk’s $10 billion takeoverPfizer is increasing its offer for Metsera. This comes after a judge rejected Pfizer's attempt to stop rival Novo Nordisk's bid. Pfizer's d...
- Pfizer, Novo Nordisk escalate bidding war for obesity drug developer MetseraA fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers...
- Pfizer sues Metsera, Novo Nordisk over rival obesity drug bidPfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...
- European stocks set to wipe out weekly gains as banks plungeEuropean shares tumbled on Friday, on course for their biggest drop in six weeks, as renewed concerns about the health of U.S. regional ban...
- Eli Lilly plans to launch experimental weight-loss pill in India, says executiveLilly's orforglipron is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company's blockbuster injection tirzepatid...
- European shares flat as investors await Ukraine talksEuropean shares were little changed in early trade on Monday, with investors on the watch for Ukraine and European leaders' meeting with U....
- Novo Nordisk owner joins the race for Healthium MedtechNovo Holdings is the latest challenger in a hotly contested bidding process for Healthium, 99.8% owned by Apax Partners. Buyout funds KKR, ...
- AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolioAstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims ...
Load More
